Treatments for Plaque Psoriasis

The Food and Drug Administration accepted a new drug application for IDP-118 lotion (halobetasol propionate and tazarotene, Ortho Dermatologics), for the topical treatment of plaque psoriasis.

NEJM analysis proves what has been suspected for decades: Alcohol can be more deadly in the psoriasis population as compared to non-psoriasis patients.

Dermatologists need to be aware of margin of error and related issues that can affect the results of biosimilar clinical trials, a study shows.

A retrospective review of pediatric patients treated for psoriasis with systemic agents provides much needed insight about the safety and tolerability of these medications.

Survey highlights the challenges of controlling psoriasis flares.

Experts from around the world will gather in London at the Psoriasis from Gene to Clinic Congress to present and discuss the most current developments in the understanding of psoriasis and the evidence that will steer future clinical decision making. Watch here for highlights.

The American College of Rheumatology annual meeting wrapped this month in San Diego. Results from long-awaited safety trials show promising new treatments.

Switching from originator to biosimilar shows no significant impact on drug survival in plaque psoriasis, but outcomes differ, researchers report.

A pediatric dermatologist addresses important differences in children with psoriasis, versus adults.

The IL-23 inhibitor risankizumab was superior to ustekinumab in a phase two trial of adult patients with moderate-to-severe chronic plaque psoriasis, researchers report. (©FreeBirdPhotos/Shutterstock.com)

New research offers strong evidence that vascular inflammation and risk of having a major adverse cardiovascular event increases with psoriasis duration.

Of several biologic agents that women of reproductive age can choose from to treat and manage psoriasis, not all have the same safety profile during pregnancy and lactation periods.

Metabolomics could provide new statistical methods to help monitor psoriasis disease and progression.

A global community of physicians cooperated to share experiences with systemic drugs for pediatric psoriasis, and to get experience with a joint registry. A uniform dataset could be tapped to learn more about disease manifestations and treatment outcomes

Psoriatic arthritis can often go undiagnosed in patients with psoriasis, and an earlier diagnosis is critical to prevent the adverse effects of psoriatic arthritis, according to an expert.

The approval of abatacept (Orencia/Bristol-Myers Squibb) for psoriatic arthritis (PsA) earlier this month by the FDA offers a new treatment option for patients who are struggling to keep the disease under control.

A novel cell-based strategy tested in mice can detect the onset of psoriasis flares by measuring disease biomarkers and then release therapeutic proteins to stop progression. Future implications are exciting.

As research advances understanding of psoriasis, drug development evolves to address various pathways to disease. A number of possibilities, now in clinical trials, appear safe, effective and promising with improved long-term clearance rates.

Newer medications have revolutionized psoriasis care in patients with moderate-to-severe cases, says a leading dermatologist, and more drugs in the pipeline promise to offer even more choices.

Researchers have uncovered new information about the pathogenetic similarities and differences between cutaneous psoriasis and psoriatic arthritis in a recent study. They hope the information, one day, leads to a test to help doctors determine which psoriasis patients will advance with psoriatic disease.

Indigo naturalis is an Old-World plant with multiple uses. Used in China for centuries as a traditional medicine, current clinical studies are proving its effectiveness as well as identifying mechanisms of action.

Dermatologists could be making greater use of topical retinoids and vitamin D preparations in treating a variety of hyperproliferative and other skin disorders. In the early days of psoriasis treatment, the “sandwich theory” focused on epidermal turnover and inflammation, with one drug or strategy for each layer.

Although many systemic immunomodulators are approved for psoriasis, their mechanisms of action suggest they have utility in indications ranging from atopic dermatitis (AD) to chronic urticaria. Understanding a systemic immunomodulator’s mechanism of action provides a theoretical basis for uses beyond its labeled indication.

Researchers analyzed emerging oral drugs for psoriasis and concluded “… the development of new oral treatments for moderate-to-severe psoriasis has not kept pace with biologic therapies.

Secukinumab has received FDA approval as a new treatment option in psoriasis. A panel of experts tackles this drug’s uses, benefits, and drawbacks.